Compare NRIX & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRIX | PRGO |
|---|---|---|
| Founded | 2009 | 1887 |
| Country | United States | Ireland |
| Employees | 357 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.0B |
| IPO Year | 2020 | 2013 |
| Metric | NRIX | PRGO |
|---|---|---|
| Price | $15.62 | $9.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $29.46 | $19.33 |
| AVG Volume (30 Days) | 690.4K | ★ 3.2M |
| Earning Date | 05-01-2026 | 05-29-2026 |
| Dividend Yield | N/A | ★ 11.82% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $76,987,000.00 | $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.32 | $1.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $8.18 | $9.70 |
| 52 Week High | $22.50 | $29.08 |
| Indicator | NRIX | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 16.79 |
| Support Level | $15.62 | N/A |
| Resistance Level | $16.47 | $14.84 |
| Average True Range (ATR) | 0.80 | 0.64 |
| MACD | 0.09 | -0.40 |
| Stochastic Oscillator | 57.14 | 2.97 |
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.